Lupin Launches Loteprednol Etabonate Eye Drops In US, Targets Seasonal Allergy Market

Lupin Ltd has officially launched Loteprednol Etabonate Ophthalmic Suspension 0.5% in the United States, following final approval from the US Food and Drug Administration. The product is a generic version of Lotemax by Bausch & Lomb and is indicated for temporary relief from seasonal allergic conjunctivitis.

Product Details And Market Scope

- The suspension is a corticosteroid used to reduce inflammation, itching, and redness caused by seasonal allergies  
- It will be manufactured at Lupin’s Pithampur facility in India  
- The reference drug, Lotemax, recorded annual US sales of USD 59 million as of February 2024  
- Lupin’s launch aims to offer a cost-effective alternative in a high-demand therapeutic segment  

Strategic Significance

- The approval strengthens Lupin’s ophthalmic portfolio and expands its footprint in the US generics market  
- It complements Lupin’s broader strategy to diversify its offerings in allergy and inflammation treatment  
- The launch follows Lupin’s recent approvals for other ophthalmic formulations, reinforcing its R&D capabilities  

Outlook

With this launch, Lupin is expected to capture a meaningful share of the seasonal allergy treatment market in the US. The move also supports its goal of enhancing access to affordable eye care solutions while boosting its North American revenue stream.

Sources: Lupin Corporate Announcements, Economic Times HealthWorld, The Health Master, Financial Express.